Across TCGA pan-cancer cohorts, KRTAP10-12 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRTAP10-12 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KRTAP10-12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP10-12 expression acts as an unfavorable survival marker.

LIHC, ESCA, and SKCM are the cancer types where KRTAP10-12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	III,IV	0.076	0.360	.001	24	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
SKCM	DFS	Median	All	0.192	0.757	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRTAP10-12 tumor-vs-normal RNA expression · all KRTAP10-12 data types